5 results about "HSP60" patented technology

The application belongs to the technical field of biological medicine, and particularly relates to application of an inhibitor for inhibiting lactic acid modification of lysine at the 249th position of HSP60 protein. The application provides application of the inhibitor for inhibiting lactic acid modification of lysine at the 249th position of HSP60 protein in preparation of a medicine for preventing and / or treating psoriasis, and an amino acid sequence of the HSP60 protein (heat shock protein 60) is shown as SEQ ID NO. 1. The application provides a brand-new, mechanism-driven psoriasis treatment target, lactic acid modification of lysine at the 249th position of HSP60 protein. By inhibiting the specific modification, the purpose of precise intervention and treatment from an upstream of the disease is achieved by stabilizing mitochondrial function and blocking intrinsic immune activation triggered by metabolic stress.

The invention discloses an application of interaction of cFKBP8-Hsp60 in depression by adjusting mitochondria. Belongs to the technical field of molecular biology and medicine, the interaction between cFKBP8 and Hsp60 is ensured, the key amino acid residue of the interaction between cFKBP8 and Hsp60 is confirmed to be the 13th arginine (cFKBP8 ARG13) of cFKBP8, and the cFKBP8 is overexpressed in SH-SY5Y cells and mouse leading edge cortical neurons by further constructing an expression vector; the results show that the mitochondrial structure and function are damaged, and the mouse shows stress susceptibility, however, the mutation of cFKBP8 ARG13 into alanine alleviates mitochondrial damage and the stress susceptibility of the mouse. Therefore, based on a molecular mechanism of adjusting mitochondria by a cFKBP8-Hsp60 axis, a new thought and a treatment target are provided for the treatment of depression.

The application belongs to the technical field of genetic engineering, and provides Hsp60 receptor targeted recombinant plant lactobacillus, a construction method and application. The plant lactobacillus is used as a host, pPG612 is used as an expression vector, and CsgB genes or CsgF genes are expressed. Two strains of engineering probiotics can express target proteins and can stably express on the surface of the bacterial body, effectively adhere to AB.9 intestinal epithelial cells, and can inhibit the adhesion and invasion of AB.9 cells. A. veronii Secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the secretion of intestinal mucus IgT. The engineering bacteria can also competitively bind to the Hsp60 receptor of intestinal epithelial cells, down-regulate the expression of p65 through the TLR4 / TLR5 dependent NF-κB signal pathway, inhibit the activation of the NF-κB signal pathway, regulate the redistribution of intestinal tight junction proteins, and down-regulate the expression of pro-inflammatory factors. Furthermore, the engineering bacteria can increase the abundance of intestinal beneficial flora of the snakehead, and the flora can mediate and activate the immune response through the feeding environment.

The present invention relates to a biomarker for predicting the prognosis of colorectal cancer by using changes in the expression level of HSPD1 gene mRNA or HSP60 protein encoded by these genes, and a method for predicting prognosis using the same. By analyzing the expression level of HSPD1 gene or HSP60 protein, the prognosis of colorectal cancer patients can be predicted in clinical practice, and by performing the analysis in combination with TNM classification, more advanced prediction is possible and personalized strategies can be designed.

The invention relates to the technical field of bioengineering, and discloses an application of a heat shock protein in preparation of a medicine for treating subarachnoid hemorrhage, and the heat shock protein is HSP60. Wherein the expression of HSP60 is up-regulated after subarachnoid hemorrhage of a mouse, and NLRP3 inflammasome assembly is promoted by activating a TLR4 / MyD88 / NF-kappa B signal channel in cells, so that pyroptosis of microglial cells is induced, and early brain injury is aggravated; the invention further provides a product for treating / inhibiting subarachnoid hemorrhage. The invention discloses a key effect of HSP60 on induction of pyroptosis of microglial cells through a TLR4 / MyD88 / NF-kappa B-NLRP3 signal axis in SAH-induced early brain injury for the first time, and proves that mizoribine can effectively relieve neuroinflammation and brain injury by inhibiting HSP60.